Research
Hormonal
GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than older pharmacotherapies (liraglutide, orlistat, phentermine/topiramate) and provide cardiovascular benefits.
If lifestyle changes alone are insufficient, newer GLP-1 medications like semaglutide (2.4 mg weekly) offer significantly higher weight loss (approx. 15%) compared to older drugs. Discuss these options with your doctor, keeping in mind that cost and insurance coverage may be barriers.
StrongSupportsVERY_HIGH confidence
Semaglutide is a major breakthrough in the treatment of obesity as the degree of weight loss achieved is nearly twice that seen with other approved anti-obesity treatments. Tirzepatide was associated with 15% weight reduction with 5 mg weekly doses, 19.5% with 10 mg doses and 20.9% with 15 mg doses... Semaglutide 2.4 mg was evaluated in the STEP trials... showed a weight loss of 14.8%... compared with 2.4% in the placebo group.
Why this rating
Supported by large RCTs (STEP, SURMOUNT) with clear, significant effect sizes.
Source
Obesity in the Asia-Pacific Region: Current Perspectives
David Tak Wai Lui et al. · Journal of Asian Pacific Society of Cardiology · 2024
narrative_reviewCited 30×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →